Detalles de la búsqueda
1.
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.
PLoS Biol
; 14(1): e1002344, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26736041
2.
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
J Immunol
; 197(12): 4829-4837, 2016 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27807190
3.
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Haematologica
; 100(1): 77-86, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344523
4.
Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".
J Immunol
; 200(8): 2517, 2018 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29632251
5.
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
J Immunol
; 187(6): 3438-47, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21841127
6.
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.
Life Sci Alliance
; 5(11)2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271507
7.
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
EBioMedicine
; 52: 102625, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31981978
8.
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
PLoS Med
; 5(3): e64, 2008 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-18366248
9.
Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.
Blood
; 112(10): 4354-5; author reply 4355-6, 2008 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18988880
10.
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.
MAbs
; 7(4): 672-80, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26037225
11.
A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab.
J Immunol Methods
; 388(1-2): 8-17, 2013 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23183273
Resultados
1 -
11
de 11
1
Próxima >
>>